A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia.
A diverse body of evidence suggests that lycopene might inhibit prostate cancer development. We conducted a 6-mo repeat biopsy randomized trial among men with high-grade prostatic intraepithelial neoplasia (HGPIN). Here we report results for serum lycopene, prostate specific antigen (PSA) and insuli...
| Publicado en: | Nutrition & Cancer Vol. 67; no. 7; pp. 1104 - 1113 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Taylor & Francis Ltd
Oct2015
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=110072106&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 110072106 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01635581 7MS jtl: Nutrition & Cancer issn: 01635581 maglogo: N pubinfo: dt: Oct2015 vid: 67 iid: 7 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 110072106 110072106 110072106 10.1080/01635581.2015.1075560 NLM26422197 110072106 ppf: 1104 ppct: 9 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia. aug: au: Gann, Peter H. Deaton, Ryan J. Rueter, Erika Enk van Breemen, Richard B. Nonn, Larisa Macias, Virgilia Han, Misop Ananthanarayanan, Viju affil: Department of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA sug: subj: Lycopene Plant Extracts Prostatic Neoplasms Physiopathology Randomized Controlled Trials Human Tomatoes Therapeutic Use Male Prostatic Neoplasms Classification Prostate Anatomy and Histology Prostatic Neoplasms Prevention and Control Proteins Patient Selection Specimen Handling Diagnosis, Laboratory Immunohistochemistry Data Analysis Biopsy Blood Chemical Analysis Race Factors Ethnic Groups Growth Substances Prostatic Neoplasms Therapy Funding Source Male ab: A diverse body of evidence suggests that lycopene might inhibit prostate cancer development. We conducted a 6-mo repeat biopsy randomized trial among men with high-grade prostatic intraepithelial neoplasia (HGPIN). Here we report results for serum lycopene, prostate specific antigen (PSA) and insulin-like growth factor (IGF) proteins, histopathological review, and tissue markers for proliferation [minichromosome maintenance protein 2 (MCM-2)] and cell cycle inhibition (p27). Participants consumed placebo or tomato extract capsules containing 30 mg/day lycopene. Pre- and posttreatment biopsies were immunostained and digitally scored. Serum lycopene was determined by LC-MS-MS. In secondary analyses, pathologists blindly reviewed each biopsy to score histological features. Fifty-eight men completed the trial. Serum lycopene increased 0.55 μmol/L with treatment and declined 0.29 μmol/L with placebo. We observed no meaningful differences in PSA, IGF-1, or IGF binding protein 3 concentrations between groups, nor any differences in expression of MCM-2 or p27 in epithelial nuclei. Prevalences of cancer, HGPIN, atrophy, or inflammation posttreatment were similar; however, more extensive atrophy and less extensive HGPIN was more common in the lycopene group. Despite large differences in serum lycopene following intervention, no treatment effects were apparent on either the serum or benign tissue endpoints. Larger studies are warranted to determine whether changes observed in extent of HGPIN and focal atrophy can be replicated. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|